Drug Oncology

Tibsovo

Payments companies reported to CMS as associated with Tibsovo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.3Massociated payments (2023-2025)
4,233clinicians with associated payments
5companies reporting

By year

2023 $515K
2024 $401K
2025 $402K

Payments reported as associated with Tibsovo, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $587K
Medical Oncology $246K
Hematology (Internal Medicine) $191K
Internal Medicine $100K
Anatomic Pathology & Clinical Pathology $32K
Nurse Practitioner $26K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Tibsovo

These are the largest totals companies reported as associated with Tibsovo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Thomas Leblanc Durham, NC Medical Oncology $70,429.00
Harry Erba Ann Arbor, MI Medical Oncology $59,612.25
Eytan Stein New York, NY Internal Medicine $56,985.90
Rami Komrokji Tampa, FL Hematology (Internal Medicine) $47,487.73
Michael Morse Durham, NC Hematology & Oncology $38,961.52
Jamie Koprivnikar Hackensack, NJ Medical Oncology $31,884.72
Michael Bishop Chicago, IL Hematology & Oncology $30,236.22
Bruce Smith Baltimore, MD Medical Oncology $25,764.23
Courtney Dinardo Houston, TX Hematology & Oncology $24,907.91
John Quigley Chicago, IL Hematology (Internal Medicine) $24,178.71

Prescribed Tibsovo?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.